BCL2 and hematologic disorder: Because BCL-2 inhibitor venetoclax is the only agent that has already been approved for the treatment of patients with hematologic malignancies, we will focus only on mechanisms of sensitivity/resistance to BCL-2 inhibition by venetoclax.